Hysobrid Kid Tablet DT contains Sultamicillin tosilate 250 mg, a combination antibiotic comprising ampicillin and sulbactam in a prodrug form, designed for pediatric use. This formulation offers enhanced bioavailability and is effective against a broad spectrum of bacterial infections caused by susceptible strains of both gram-positive and gram-negative organisms. Sultamicillin acts by inhibiting bacterial cell wall synthesis, while sulbactam serves as a beta-lactamase inhibitor, thereby extending the antibiotic spectrum by protecting ampicillin from enzymatic degradation. Hysobrid Kid Tablet DT is indicated for the treatment of respiratory tract infections, otitis media, urinary tract infections, skin and soft tissue infections, and other bacterial infections in children where beta-lactamase-producing pathogens are suspected. The tablet is designed for rapid disintegration in the oral cavity, facilitating ease of administration in pediatric patients who may have difficulty swallowing conventional tablets. Dosage and duration of therapy should be determined by a healthcare professional based on the severity of infection and patient-specific factors. Caution is advised in patients with a history of hypersensitivity to penicillins or cephalosporins. Common adverse effects may include gastrointestinal disturbances and hypersensitivity reactions. Proper adherence to prescribed therapy is essential to prevent resistance development.